111 related articles for article (PubMed ID: 3350834)
21. Effect of the antiarrhythmic drug procainamide on the toxicity and antitumor activity of cis-diamminedichloroplatinum(II).
Esposito M; Viale M; Vannozzi MO; Zicca A; Cadoni A; Merlo F; Gogioso L
Toxicol Appl Pharmacol; 1996 Oct; 140(2):370-7. PubMed ID: 8887454
[TBL] [Abstract][Full Text] [Related]
22. Differential alteration of cisplatin cytotoxicity and myelotoxicity by the paclitaxel vehicle cremophor EL.
Badary OA; Abdel-Naim AB; Khalifa AE; Hamada FM
Naunyn Schmiedebergs Arch Pharmacol; 2000 Mar; 361(3):339-44. PubMed ID: 10731049
[TBL] [Abstract][Full Text] [Related]
23. Drug interaction effects on antitumor drugs. XIII. Amelioration of cisplatin lethality and renal toxicity by chlorpromazine in mice.
Ishikawa M; Takayanagi Y; Sasaki K
Biol Pharm Bull; 1993 Nov; 16(11):1104-7. PubMed ID: 8312864
[TBL] [Abstract][Full Text] [Related]
24. Protection against cisplatin nephrotoxicity by prochlorperazine.
Kramer RA
Cancer Chemother Pharmacol; 1989; 25(3):156-60. PubMed ID: 2598405
[TBL] [Abstract][Full Text] [Related]
25. Lentinan enhances sensitivity of mouse colon 26 tumor to cis-diamminedichloroplatinum (II) and decreases glutathione transferase expression.
Murata T; Hatayama I; Kakizaki I; Satoh K; Sato K; Tsuchida S
Jpn J Cancer Res; 1996 Nov; 87(11):1171-8. PubMed ID: 9045947
[TBL] [Abstract][Full Text] [Related]
26. Antitumor effect of cisplatin incorporated into polylactic acid microcapsules.
Araki H; Tani T; Kodama M
Artif Organs; 1999 Feb; 23(2):161-8. PubMed ID: 10027886
[TBL] [Abstract][Full Text] [Related]
27. Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts.
Kudoh S; Takada M; Masuda N; Nakagawa K; Itoh K; Kusunoki Y; Negoro S; Matsui K; Takifuji N; Morino H
Jpn J Cancer Res; 1993 Feb; 84(2):203-7. PubMed ID: 8385085
[TBL] [Abstract][Full Text] [Related]
28. Potentiation by interleukin 1 alpha of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in the RIF-1 tumor model.
Chang MJ; Yu WD; Reyno LM; Modzelewski RA; Egorin MJ; Erkmen K; Vlock DR; Furmanski P; Johnson CS
Cancer Res; 1994 Oct; 54(20):5380-6. PubMed ID: 7923169
[TBL] [Abstract][Full Text] [Related]
29. Correlation of the in vitro cytotoxicity of ethyldeshydroxysparsomycin and cisplatin with the in vivo antitumour activity in murine L1210 leukaemia and two resistant L1210 subclones.
Hofs HP; Wagener DJ; de Valk-Bakker V; van Rennes H; van Zeist AJ; van den Broek LA; Ottenheijm HC
Cancer Chemother Pharmacol; 1993; 31(4):289-94. PubMed ID: 8422692
[TBL] [Abstract][Full Text] [Related]
30. Increase in E-selectin expression in umbilical vein endothelial cells by anticancer drugs and inhibition by cimetidine.
Kawase J; Ozawa S; Kobayashi K; Imaeda Y; Umemoto S; Matsumoto S; Ueda M
Oncol Rep; 2009 Dec; 22(6):1293-7. PubMed ID: 19885579
[TBL] [Abstract][Full Text] [Related]
31. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.
Dai G; Deng S; Guo W; Yu L; Yang J; Zhou S; Gao T
Mol Carcinog; 2019 Jan; 58(1):3-18. PubMed ID: 29964327
[TBL] [Abstract][Full Text] [Related]
32. Polypeptide-based combination of paclitaxel and cisplatin for enhanced chemotherapy efficacy and reduced side-effects.
Song W; Tang Z; Li M; Lv S; Sun H; Deng M; Liu H; Chen X
Acta Biomater; 2014 Mar; 10(3):1392-402. PubMed ID: 24316362
[TBL] [Abstract][Full Text] [Related]
33. Antitumor effectiveness and toxicity of cisplatin-loaded long-circulating and pH-sensitive liposomes against Ehrlich ascitic tumor.
de Carvalho Maroni L; de Oliveira Silveira AC; Leite EA; Melo MM; de Carvalho Ribeiro AF; Cassali GD; de Souza CM; Souza-Fagundes EM; Caldas IR; Araújo MS; Martins-Filho OA; de Oliveira MC; Teixeira-Carvalho A
Exp Biol Med (Maywood); 2012 Aug; 237(8):973-84. PubMed ID: 22903135
[TBL] [Abstract][Full Text] [Related]
34. Pentoxifylline potentiates the antitumor effect of cisplatin and etoposide on human lung cancer cell lines.
Ohsaki Y; Ishida S; Fujikane T; Kikuchi K
Oncology; 1996; 53(4):327-33. PubMed ID: 8692539
[TBL] [Abstract][Full Text] [Related]
35. Cisplatin-incorporated polymeric micelles eliminate nephrotoxicity, while maintaining antitumor activity.
Mizumura Y; Matsumura Y; Hamaguchi T; Nishiyama N; Kataoka K; Kawaguchi T; Hrushesky WJ; Moriyasu F; Kakizoe T
Jpn J Cancer Res; 2001 Mar; 92(3):328-36. PubMed ID: 11267944
[TBL] [Abstract][Full Text] [Related]
36. [The effect of zinc glycyrrhizate on toxicity and anticancer activity of cisplatin in mice].
Xu ZL; Guo JH; Song ST; Li MJ; Wu DZ
Yao Xue Xue Bao; 1993; 28(8):567-71. PubMed ID: 8285063
[TBL] [Abstract][Full Text] [Related]
37. The protective potential of the combination of verapamil and cimetidine on cisplatin-induced nephrotoxicity in man.
Sleijfer DT; Offerman JJ; Mulder NH; Verweij M; van der Hem GK; Schraffordt Koops HS; Meijer S
Cancer; 1987 Dec; 60(11):2823-8. PubMed ID: 3677015
[TBL] [Abstract][Full Text] [Related]
38. Advantages in combination chemotherapy using cisplatin and its analogues for human testicular tumor xenografts.
Hida S; Okada K; Yoshida O
Jpn J Cancer Res; 1990 Apr; 81(4):425-30. PubMed ID: 2114395
[TBL] [Abstract][Full Text] [Related]
39. Prevention of cisplatin-induced toxicity by selected dithiocarbamates.
Walker EM; Fazekas-May MA; Heard KW; Yee S; Montague D; Jones MM
Ann Clin Lab Sci; 1994; 24(2):121-33. PubMed ID: 8203821
[TBL] [Abstract][Full Text] [Related]
40. Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system.
Light BW; Yu WD; McElwain MC; Russell DM; Trump DL; Johnson CS
Cancer Res; 1997 Sep; 57(17):3759-64. PubMed ID: 9288784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
